22nd International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV

第22届艾滋病毒合并症和药物不良反应国际研讨会

• 批准号: 10082909
• 负责人: TODD T BROWN
• 金额: $ 4.3万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-24 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10082909
• 关键词: Adverse effects; Age; Cardiovascular Diseases; Cause of Death; Chronic; Chronic Disease; Clinical; Clinical Management; Collaborations; Committee Members; Communities; Disease; Educational workshop; Endocrinologist; Etiology; Europe; Feedback; Fostering; Goals; HIV; HIV Infections; Home environment; Inflammation; International; International AIDS; Internet; Liver diseases; Longevity; Mentors; Metabolic Bone Diseases; Metabolism; Molecular; New York; New York City; Obesity; Opportunistic Infections; Oral; Paper; Pathogenesis; Play; Research; Research Personnel; Retroviridae Infections; Risk Factors; Role; Scholarship; Sleep; Societies; Stroke; Training Programs; Translational Research; Travel; Ursidae Family; Work; adverse drug reaction; antiretroviral therapy; career development; clinical practice; co-infection; comorbidity; disability; healthspan; improved; low and middle-income countries; meetings; pediatric cardiologist; peer; posters; programs; research clinical testing; skills; success; symposium

With the success of antiretroviral therapy (ART), comorbid diseases are now the leading causes of death and disability in people living with HIV around the globe, including low and middle income countries (LMIC). Large meetings, such as the Conference for Retroviruses and Opportunistic Infections and the International AIDS Society Conference, are important venues for scientific exchange regarding the latest advances in HIV Comorbidity research, but smaller, more intimate formats that emphasize discussion and networking are critical to the career development of HIV Comorbidity investigators. The International Workshop for Comorbidities and Adverse Drug Reactions in HIV, now in its 22nd year, provides <200 delegates with an opportunity to come together to discuss the latest findings and controversies in HIV Comorbidity research in one-room, two-day format. Plenary speakers are either noted experts from outside of HIV research or HIV researchers with expertise in a specific comorbidity. Abstract presentations including 24 15-minute talks and a poster session provide ample opportunity for researchers to present and get feedback on their latest work. With this R13, we propose to enhance the 22nd Workshop (September 12th/13th in New York) with the following aims: 1) to provide a forum for the latest HIV Comorbidity research in LMIC by offering travel scholarships to LMIC investigators, supporting an internationally-recognized expert in non-communicable diseases in LMIC as a plenary speaker, and liaising with international training programs, 2) to support early-stage investigators with a scholarship program and a research skill building workshop, and guided poster tour, 3) to increase the impact of the Workshop through the webcast of plenary and abstract presentations. By providing a “scientific home” to an increasing number of HIV Comorbidity investigators from around the world, we hope to catalyze future research efforts in HIV Comorbidities and facilitate the translation of research findings into clinical strategies that can improve the lifespan and health span of PLWH.

随着抗逆转录病毒疗法 (ART) 的成功，合并症现已成为主要原因 全球艾滋病毒感染者（包括中低收入人群）的死亡和残疾率 收入国家（LMIC）。大型会议，例如逆转录病毒会议和 机会性感染和国际艾滋病协会会议是重要的场所 关于艾滋病毒合并症研究最新进展的科学交流，但规模较小， 强调讨论和交流的更亲密的形式对于职业生涯至关重要 艾滋病毒合并症调查人员的发展。国际合并症研讨会 和艾滋病毒药物不良反应，现已进入第 22 个年头，为 <200 名代表提供了 有机会聚在一起讨论艾滋病毒合并症的最新发现和争议 以一间房间、两天的形式进行研究。全体发言者要么是来自外部的著名专家 具有特定合并症专业知识的 HIV 研究人员或 HIV 研究人员。抽象的 演讲包括 24 个 15 分钟的演讲和海报会议，为他们提供了充足的机会 研究人员展示他们的最新工作并获得反馈。对于这个 R13，我们建议 加强第 22 次研讨会（9 月 12 日/13 日在纽约），目标如下：1) 通过提供旅行奖学金，为中低收入国家的最新艾滋病毒合并症研究提供论坛 向中低收入国家研究人员提供支持，支持国际公认的非传染性疾病专家 作为全体会议发言人介绍中低收入国家的疾病，并与国际培训项目联络，2) 通过奖学金计划和研究技能建设来支持早期研究人员 研讨会和海报导览，3) 通过 全体会议和摘要演示的网络直播。通过为越来越多的人提供一个“科学之家” 来自世界各地的艾滋病毒合并症调查人员数量，我们希望促进未来 艾滋病毒合并症的研究工作，并促进研究结果转化为 可以延长 PLWH 寿命和健康寿命的临床策略。